ICHR ICHOR HOLDINGS, LTD. Insider Trading

CEO Philip Ryan Sr. Barros sells 13,705 ICHR shares at $70.19 via 10b5-1 plan; retains 165,078 shares

Philip Ryan Sr. Barros, Chief Executive Officer of Ichor Holdings, sold 13,705 shares at $70.19 on 2026-06-04 as part of a pre-arranged 10b5-1 trading plan, reducing his direct holdings to 165,078 shares. The transaction is scheduled and non-discretionary. The sale occurred while the stock trades at $62.91, down -19.4% from its 52-week high of $78.00 and down -13.2% over the past 30 days, though it has gained +57.2% over 90 days. The company reported net income of $-2.5M in its latest quarter and remains unprofitable on a full-year basis despite +11.6% annual revenue growth, which may warrant investor scrutiny of near-term profitability trajectory.

Director Laura A. Black sold 20,000 shares of ICHR at $75.02 for $1,500,400.00, reducing holdings by 49.4%.

Director Laura A. Black sold 20,000 shares at $75.02 on 2026-06-02, cutting her position in half from 40,462 to 20,462 shares. The sale came as ICHOR reported a latest quarterly revenue of $256,068,000.00 with net income of -$2,469,000.00, following a fiscal year of negative full-year net income despite annual revenue growth of +11.6%. At the time of sale, the stock was trading near its 52-week high of $78.00 (current price $74.95 is -3.9% from that peak), having risen 60.7% over the prior 90 days and 16.4% over the prior 30 days.

CFO Greg Swyt sold 19,662 shares of ICHR at $70.42 for $1,384,598.04 under pre-arranged 10b5-1 plan

Greg Swyt, CFO of Ichor Holdings, executed a sale of 19,662 shares at $70.42 on 2026-05-28 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 80,633 shares to 60,971 shares. This is a scheduled transaction, not a discretionary decision. The company's recent financials show revenue of $256,068,000 in the latest quarter with net income of $-2,469,000, indicating current unprofitability despite annual revenue growth of +11.6%. The stock's 90-day performance of +50.4% reflects significant momentum prior to this sale, occurring near the 52-week high of $78.00.

ICHR CEO Barros sold 21,000 shares at $46.63; stock up 54% in 30d, 183% in 90d; prior 2 ICHR sales were well-timed (-16.8%, -24.9% 90d returns)

Chief Executive Officer Philip Ryan Barros Sr. sold 21,000 shares (12.0% of pre-transaction holdings) on 2026-02-26 at $46.63, reducing his position to 153.9K shares. The stock has surged 54.0% over the past 30 days and 183.0% over the past 90 days, reaching within 11.2% of its 52-week high of $53.58. His prior two sales at ICHR both proved well-timed against subsequent price declines: the 2024-12-02 sale saw a -16.8% 90-day return, and the 2023-09-06 sale saw a -24.9% 90-day return. However, the company remains unprofitable (net income of -$22.9M in the latest quarter) despite 11.6% annual revenue growth, creating ambiguity about whether this sale reflects reaction to fundamental weakness or portfolio rebalancing amid recent strong momentum. The timing of this sale during an extended rally—when the stock has climbed from $14.06 toward recent highs—aligns with his historical pattern of selling before declines, warranting attention to whether this signals his assessment of near-term valuation risk.

COO Bruce Ragsdale sells 21,276 shares ($1.1M) at $49.66; holdings fall to 97,661 shares (-17.9%) as stock near 52-week highs.

RAGSDALE BRUCE, Chief Operating Officer, sold 21,276 shares at $49.66 on 2026-02-23, reducing holdings from 118,937 to 97,661 shares. The transaction's timing occurs with the stock at $52.41 current price and within 2.2% of its 52-week high of $53.58, amid a 71.3% 30-day rally and 213.8% 90-day surge. However, the company reported a net loss of $-22,853,000.00 in its most recent quarter and unprofitability over the full fiscal year, even as annual revenue grew 11.6% to $239,296,000.00. This sale by a C-suite executive during a sharp price appreciation phase, against a backdrop of ongoing operating losses, is a data point that merits scrutiny of the fundamental trajectory and investor positioning.

Director Rohrs sells 53.9K shares (50.4% of holdings) at $45.48; prior 4 sells at ICHR all well-timed, stock +68.1% 30d but unprofitable.

Thomas M. Rohrs, a director, divested exactly half his ICHR position, selling 53,908 shares at $45.48 on 2026-02-12, leaving him with 53,024 shares. His prior four sales at this same ticker (2025, 2024, 2023) were all well-timed at the 90-day mark, with post-sale declines ranging from -16.0% to -44.8%. The company is currently unprofitable (net income $-22,853,000.00 for the latest full year) and reported net losses of $-22,853,000.00 in the most recent quarter. The stock has surged +68.1% over the past 30 days and +200.1% over 90 days—well above its 52-week high of $47.59 by the transaction date, placing the sale at a notably elevated price level. Rohrs' historical pattern of well-timed exits at this ticker (100% success rate across 4 prior trades) combined with the aggressive recent rally into an unprofitable business suggests the market may have priced in optimism that warrants investor scrutiny.

Director MacKenzie Iain bought 10,000 ICHR shares at $14.53; stock down -35.0% in 30 days, now -59.6% from 52-week high.

MacKenzie Iain, a Director, purchased 10,000 shares of ICHOR HOLDINGS at $14.53 on 2025-11-17, increasing his holdings by 8.3% to 130,011 shares. This marks his second consecutive open-market buy at ICHR within 11 days (following a purchase on 2025-11-06), and his prior same-ticker buy on 2025-08-07 posted a positive 90-day return of +0.4%. However, the current trading environment presents a sharp headwind: the stock has declined -35.0% in the 30 days since this purchase and trades -59.6% below its 52-week high of $35.40, now at $14.29. The company generated $239.3M in quarterly revenue with annual revenue growth of +4.7%, but remains unprofitable, reporting a net loss of $-22.9M over its most recent full fiscal year. The timing and magnitude of the recent price decline warrant attention to whether the director's sequential buying reflects conviction at depressed levels or exposure to deteriorating conditions.

ICHR Director MacKenzie Iain bought 10.0K shares at $15.28; stock now -56.4% from 52-week high and unprofitable.

MacKenzie Iain, as a director of Ichor Holdings, purchased 10,000 shares at $15.28, increasing his holdings by 9.1% to 120.0K shares. The transaction occurs amid significant headwinds: the stock is trading -56.4% from its 52-week high of $35.40, down 15.7% over the past 30 days and 18.5% over 90 days, while the company reported a net loss of $-22.9M on $239.3M in quarterly revenue. His prior buy at this ticker on 2025-08-07 delivered a 90-day return of +0.4%, and his cross-ticker buy history shows a 100% 90-day win rate with an average 90-day return of +0.4%. The purchase occurs as the stock has experienced substantial depreciation, but without scheduled transaction disclosures in the filing facts, the timing relative to upcoming catalysts or fundamental inflection points remains unclear to investors.

Director Haugen Marc bought 6,000 shares at blended $17.70 (filed 2025-08-07); stock now $16.06, down -32.4% (30-day).

Director Marc Haugen purchased 6,000 shares across two transactions on 2025-08-07 and 2025-08-08 at a blended average price of $17.70, increasing his holdings by 15.0% to 46.0K shares. The stock has since declined to $16.06, trading 54.6% below its 52-week high and down 32.4% over the past 30 days. The company is unprofitable (net income $-9.4M on revenue $240.3M) despite modest 4.7% annual revenue growth, suggesting operational headwinds. The timing of this purchase during a steep near-term decline warrants examination of whether this reflects genuine operational conviction or represents buying into sustained negative momentum.

Director MacKenzie Iain purchased 25,000 shares of ICHR at $16.63, raising stake 71.4% to 60,011 shares amid steep 54.6% decline from 52-week high.

MacKenzie Iain, a Director, acquired 25,000 shares of ICHOR HOLDINGS for $415,750.00, expanding his holdings by 71.4% from 35,011 to 60,011 shares. The transaction occurs against a backdrop of significant near-term weakness: the stock is down 32.4% over the past 30 days and has fallen 54.6% from its 52-week high of $35.40. The company is unprofitable, with the most recent full fiscal year showing net income of $-9,408,000.00, though revenue growth remains positive at 4.7% year-over-year. This insider purchase at a substantially depressed price level relative to recent history warrants attention regarding both the company's valuation inflection and the director's assessment of intrinsic value amid operational challenges.